uniQure Announces Proposed Public Offering
September 04 2019 - 4:02PM
uniQure N.V. (Nasdaq: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe unmet
medical needs, today announced that it has commenced an
underwritten public offering of $200 million of its ordinary
shares. All ordinary shares to be sold in the offering will be
offered by uniQure. In addition, uniQure intends to grant the
underwriters a 30-day option to purchase up to $30 million of
additional ordinary shares at the public offering price, less
underwriting discounts and commissions. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Goldman Sachs & Co. LLC and SVB Leerink are
acting as joint book-running managers for the offering. Stifel is
also acting as a book-running manager. Cantor Fitzgerald & Co.
and SunTrust Robinson Humphrey are acting as co-lead managers for
the offering and H.C. Wainwright & Co. is acting as the
co-manager for the offering.
The securities described above are being offered
by uniQure pursuant to its automatically effective shelf
registration statement on Form S-3 (File No. 333-225636) filed with
the Securities Exchange Commission (the “SEC”) on June 14,
2018. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and
will be available for free on the SEC’s website at
http://www.sec.gov. When available, copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282,
telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com, SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525 ext. 6132 or by email at
syndicate@svbleerink.com, and Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite
3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by
email at syndprospectus@stifel.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities, in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer,
if at all, will be made only by means of the prospectus supplement
and accompanying prospectus forming a part of the effective
registration statement.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. We
are leveraging our modular and validated technology platform to
rapidly advance a pipeline of proprietary gene therapies to treat
patients with hemophilia B, hemophilia A, Huntington's disease,
Fabry disease, spinocerebellar ataxia Type 3 and other
diseases.
Forward-Looking Statement
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements include, without limitation,
statements regarding our anticipated offering and other statements
including the words “may,” “will,” “intend,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances), which constitute and
are intended to identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: the uncertainties related to market conditions
and the completion of the public offering on the anticipated terms,
or at all, continued interest in our rare disease portfolio, the
ability to develop our product candidates and technologies, the
impact of changes in the financial markets and global economic
conditions, and other risks as are set forth in uniQure’s Quarterly
Report on Form 10-Q filed on July 29, 2019. uniQure undertakes no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as
a result of new information, future developments or otherwise.
uniQure Contacts
For
Investors: |
|
|
|
For
Media: |
|
|
|
|
|
Maria CantorDirect : +339-970-7536Mobile:
617-680-9452m.cantor@uniQure.com |
|
Eva M. MulderDirect: +31 20 240 6103Mobile:
+31 6 52 33 15 79e.mulder@uniQure.com |
|
Tom MaloneDirect: 339-970-7758Mobile:
339-223-8541t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024